The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study

IntroductionCadonilimab provides substantial clinical benefits in recurrent or metastatic cervical cancer (R/M CC) in several clinical trials and meeting abstracts. However, the efficacy of cadonilimab in patients with prior failure of anti- programmed death receptor-1 (PD-1) inhibitors, as well as...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Frontiers in Immunology
Main Authors: Baoyue Pan, He Huang, Ting Wan, Qidan Huang, Shanyang He, Shijie Xu, Siyu Chen, Jiaxin Yin, Jundong Li, Min Zheng
Formato: Artigo
Publicado em: Frontiers Media S.A. 2025-06-01
Assuntos:
Cadonilimab
Anti-PD-1
Anti-PD-1/CTLA-4
Cervical cancer
Immune checkpoint inhibitor
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1582299/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1582299/full

Registos relacionados